Unicycive Faces Class Action After FDA Rejection
Unicycive Therapeutics is under legal scrutiny following a 39% stock drop triggered by the FDA's rejection of its kidney disease drug resubmission.
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) faces a class action lawsuit alleging it misled investors about the compliance status of its third-party manufacturing vendor. The complaint, filed by Kaplan Fox & Kilsheimer LLP, covers securities transactions between December 29, 2025, and June 29, 2026. The firm claims the company failed to disclose that it had not audited the vendor’s facility for current good manufacturing practices, leaving it without a reasonable basis to believe previous FDA deficiencies were resolved.
The legal action follows a sharp market decline on June 30, 2026, when the FDA issued a Complete Response Letter regarding oxylanthanum carbonate. The agency cited the same third-party manufacturing deficiencies identified in a prior letter from June 2025. Unicycive’s share price dropped $3.01, or 39.1%, to close at $4.69 per share on unusually heavy volume. The lawsuit suggests the company made false statements about its oversight of the vendor during the class period.
FDA Rejection Triggers Market Loss
The core of the dispute centers on the failure of the resubmitted New Drug Application for the company’s kidney disease therapy. According to the complaint, Unicycive did not inspect the vendor’s facility or audit its compliance with regulatory standards. This lack of verification meant the company could not reasonably assert that the manufacturer had corrected the issues flagged by the FDA in 2025. The resulting rejection exposed the gap between the company's public assurances and its actual operational oversight.
Investors Have November Filing Deadline
Potential class members must act by November 2, 2026, if they wish to seek the position of lead plaintiff. This role involves directing the litigation strategy for the group. Investors who suffered losses during the specified period may contact Kaplan Fox to learn more about their legal rights. Participation in the class does not require seeking the lead plaintiff position to share in any potential recovery, as reported by GN stocks/nasdaq.
Law Firm Cites Litigation History
Kaplan Fox & Kilsheimer LLP, established in 1956, represents the proposed class in this securities matter. The firm states it has recovered over $10 billion for clients in complex litigation, including significant settlements in antitrust and consumer protection cases. Its team focuses on prosecuting actions in federal and state courts, handling high-stakes disputes for institutional investors and individuals.
